New Mathematical Modeling Approach To Analyzing Colorectal Cancer Clinical Trial Data
Researchers estimated several tumor-size response metrics using longitudinal tumor-size models and data from two Phase III clinical trials, which compared bevacizumab with chemotherapy versus chemotherapy alone as first-line therapy for colorectal cancer. Trial participants included 923 Western and 203 Chinese patients. Baseline prognostic factors and the tumor-size metric estimates were assessed in multivariate models to predict overall survival. Multiple simulations of the Phase III studies were used to test the models' predictive capabilities.
Time to tumor growth proved to be the best metric for predicting overall survival. The proposed model worked equally well when predicting overall survival rates for the Western and Chinese patients and as such could be used to support drug development decisions in either population.
René Bruno, Ph.D., managing director of Certara's Pharsight Consulting Services Europe, and senior author of the paper, said: "This approach of combining modeling with longitudinal tumor-size data may contribute to improved design and analysis of more informative early-stage clinical studies (Phase Ib, II). It could also enable researchers to select the most promising treatments and reduce the high attrition rate in Phase III oncology studies."
Robert Powell, PharmD, former senior advisor at Roche China, and co-author of the paper, added: "It is important to know whether patients in a new market (e.g., China, India, Brazil) will be similar to patients in the original US or EU New Drug Application (NDA). While pharmaceutical companies usually assume patients from different regions are the same, there is emerging evidence that they might be different with regard to efficacy, safety and dose response. This type of analysis helps better define Chinese colon cancer response relative to Western patients. Roche performed this combined Chinese and US NDA study analysis to learn whether Chinese patients responded similarly to Western patients so they can use this information to plan future trials. Likewise knowing these results will be important to local regulatory agencies such as the China Food and Drug Administration in this case."
Rana Healthcare Solutions LLC
Source: EurekAlert!, the online, global news service operated by AAAS, the science society
Please use one of the following formats to cite this article in your essay, paper or report:
Rana Healthcare Solutions LLC. "New Mathematical Modeling Approach To Analyzing Colorectal Cancer Clinical Trial Data." Medical News Today. MediLexicon, Intl., 11 May. 2013. Web.
27 May. 2016. <http://www.medicalnewstoday.com/releases/260331.php>
Rana Healthcare Solutions LLC. (2013, May 11). "New Mathematical Modeling Approach To Analyzing Colorectal Cancer Clinical Trial Data." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.